Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-19T21:54:08.637Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabotropic glutamate receptor agonists for schizophrenia

Published online by Cambridge University Press:  02 January 2018

Paul J. Harrison
Paul J. Harrison*
Affiliation:
Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. Email: paul.harrison@psych.ox.ac.uk
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A drug acting at metabotropic glutamate receptors has recently been reported to be an effective antipsychotic, breaking the rule that only dopamine receptor-blocking drugs have this property. The finding complements accumulating evidence that glutamatergic abnormalities are important in the pathophysiology of schizophrenia.

Type
Editorials
Information
The British Journal of Psychiatry , Volume 192 , Issue 2 , February 2008 , pp. 86 - 87
Copyright
Copyright © Royal College of Psychiatrists, 2008 

References

1 Miyamoto, S, Duncan, GE, Marx, CE, Lieberman, JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10: 79–104.Google Scholar
2 Patil, ST, Zhang, L, Martenyi, F, Lowe, SL, Jackson, KA, Andreev, BV, Avedisova, AS, Bardenstein, LM, Gurovich, IY, Morozova, MA, Mosolov, SN, Neznanov, NG, Reznik, AM, Smulevich, AB, Tochilov, VA, Johnson, BG, Monn, JA, Schoepp, DD. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med 2007; 13: 1102–7.Google Scholar
3 Rorick-Kehn, LM, Johnson, BG, Burkey, JL, Wright, RA, Calligaro, DO, Marek, GJ, Nisenbaum, ES, Catlow, JT, Kingston, AE, Giera, DD, Herin, MF, Monn, JA, McKinzie, DL, Schoepp, DD. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2007; 321: 308–17.Google Scholar
4 Palucha, A, Pilc, A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 2007; 115: 116–47.Google Scholar
5 Spooren, W, Ballard, T, Gasparini, F, Amalric, M, Mutel, V, Schreiber, R. Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 2003; 14: 257–77.Google Scholar
6 Egan, MF, Straub, RE, Goldberg, TE, Yakub, I, Callicott, JH, Hariri, AR, Mattay, VS, Bertolino, A, Hyde, TM, Shannon-Weickert, C, Akil, M, Crook, J, Vakkalanka, RK, Balkissoon, R, Gibbs, RA, Kleinman, JE, Weinberger, DR. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101: 12604–9.Google Scholar
7 Harrison, PJ, Lyon, L, Sartorius, LI, Burnet, PWJ, Lane, TA. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function, and involvement in schizophrenia. J Psychopharmacol 2008. In press.CrossRefGoogle Scholar
8 Konradi, C, Heckers, S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther 2004; 97: 153–79.Google Scholar
9 Harrison, PJ, Weinberger, DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40–68.Google Scholar
10 Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology of schizophrenia. Am J Psychiatry 2001; 158: 1367–77.Google Scholar
11 Javitt, DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004; 9: 984–97.Google ScholarPubMed
12 Tuominen, HJ, Tiihonen, J, Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 2005; 72: 225–34.CrossRefGoogle ScholarPubMed
13 Gray, JA, Roth, BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007; 12: 904–22.Google Scholar
14 Moghaddam, B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacol 2004; 174: 39–44.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.